1 Min Read
* FDA TO REVIEW ZYNQUISTA™ (SOTAGLIFLOZIN) AS POTENTIAL TREATMENT FOR TYPE 1 DIABETES
* SANOFI - TARGET FDA ACTION DATE UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA) IS ANTICIPATED TO BE MARCH 22, 2019 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.